Affiris struck a deal with GlaxoSmithKline to develop two Alzheimer’s treatments. As part of the
agreement, GSK gains a fancy protein technology that could be a boon for future molecules.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
